Our State-of-the Art
Chemistries Drive Innovation.
At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed. Our company was built upon our deep experience and know-how in this space and we are well-positioned to advance candidates against targets considered “undruggable” by RNA chemistries.
Our FLAME™ Shines
the Light on “Dark Matter”
Flamingo also has a unique discovery engine, FLAME (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the “dark matter” of the human genome.
Latest News
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics (“Flamingo”) today announced that the PEMDA-HN trial has expanded beyond the United States into the UK and Korea.
Flamingo Therapeutics (“Flamingo”) today announced a poster presentation on FLM-7523 (also referred to as FTX-001) at the Annual Congress of the European Association for Cancer Research (EACR) 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024.
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) taking place in Chicago, Illinois.
Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.
Flamingo Therapeutics (“Flamingo”) today announced its participation in the following upcoming investor and industry conferences:
Flamingo Therapeutics (“Flamingo”) today announced the appointment of Ezra Cohen, MD to its Board of Directors. Dr. Cohen is a leading medical oncologist and cancer researcher who brings unique and relevant expertise in the development of drugs, especially head and neck cancer, to the Flamingo board.
Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.
Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023:
Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.
Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company ...
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement ...